http://regulatoryaffairs.pharmaceutical ... xin-091111
It is now much easier to get to tovaxin approved by going spms route. Easier from FDA perspective and a phase iib is much cheaper. If approved, tovaxin will most certainly be used as "off label" for rrms.
It should be more attractive for a partnership now that it is fast tracked and will be a small investment for big pharma.
Can I ask, what was your experience with Tovaxin like?
It slowed, or should I say, stopped relapses and I felt it was the one thing that stopped any progression. My walk test etc. showed that if anything, I improved slightly. I have RRMS. during the blinded initial study I found out I was on the real stuff.
Been a while but last time I checked NOTHING was happening with Tovaxin but low and behold I read the "Motivator" and saw this:
During the coming year, we anticipate that other new oral medications will be submitted for evaluation and potential approval by the FDA, including teriflunomide, laquinimod, and dimethyl fumarate (BG-12). One new injectible, Lemtrada® (alemtuzumab, formerly known as Campath and given via intravenous injection), may also enter or complete the approval process. Several more injectible drugs are also on the horizon, such as ocrelizumab, daclizumab, and Tovaxin®.
What the hell did I miss? I guess I have been to involved with anti-Lingo to notice but I'm a little dumbfounded.
Can we ask how?TWG wrote:during the blinded initial study I found out I was on the real stuff.
I'm not sure where the Motivator came up with their positive spin on Tovaxin. Why in the world would that pop up if no further studies have been done, and how can it suddenly be on a track for SPMS? Maybe they are trialing in Mongolia. Sounds like a scam story to make money on their stock.
The Anti-Lingo trial has gone well. One word, Biogen! Very tight ship, very hopeful, and opposed to Opexa, no worry of the plug being pulled. No adverse effects on anyone to my knowledge and though the staff would like us to be quiet, there has been some seemingly wonderful responses to the drug. I have seen no personal improvement. I think they are gearing up for Phase 2 in 64 locations I believe. Remember Bob, this is not an M.S. therapy per say. It's design is to re-mylenate and repair Axonal (that cannot possibly be spelled right!) damage. I have 3 more visits over 3 months. No more drug just MRI, blood, etc.
Hopeful to join phase 2!
Lars AKA Still Pissed at Opexa
Do your due diligence and you would know that they have been examining their data. See presentation from September:
http://www.opexatherapeutics.com/files/ ... 202011.pdf
Explains what they have been doing very clearly. Getting Fast Tracked is not a ploy to make money. Explain how one would make money? Read the details about their options and you would know.
Tovaxin is still a viable treatment and getting SPMS approved is a gateway for using it "off label" for RRMS.
- Similar Topics
- Last post